What are Becton Dickinson's primary business segments?

Becton Dickinson operates through three main global business segments: BD Medical, which provides a broad array of medical devices; BD Diagnostics, offering products for specimen collection and diagnostic testing; and BD Biosciences, which supplies research and clinical tools for cell analysis and drug discovery.

What are the key risks and uncertainties facing Becton Dickinson?

Key risks include regional and global economic factors, intense competition and new product introductions by competitors, changes in healthcare regulations and pricing pressures, fluctuations in raw material costs and availability, potential impacts from new medical technologies (like inhaled insulin), and ongoing litigation. The company also faces risks related to international operations due to economic conditions and currency fluctuations.

Has Becton Dickinson divested any business units recently?

Yes, the company completed the sale of its Clontech unit, which was part of the BD Biosciences segment, on August 31, 2005. The results of operations for Clontech are reported as discontinued operations.

What is Becton Dickinson's approach to research and development?

BDX invests significantly in research and development to drive innovation and maintain its competitive position. In fiscal year 2005, the company spent approximately $272 million on R&D activities, conducted both internally and through collaborations with external entities.

BDX 10-K FY2005 Annual Report — Revenue, Net Income, EPS

Summary

Becton, Dickinson and Company (BDX) presents its 2005 10-K report, detailing its operations as a global medical technology company. The company is structured into three core segments: BD Medical, BD Diagnostics, and BD Biosciences, offering a wide array of products for healthcare institutions, life science researchers, and clinical laboratories. BDX highlights its commitment to innovation and its diversified product portfolio, which mitigates risks associated with specific market shifts or regulatory changes. The company's global presence, with manufacturing and sales operations in numerous countries, contributes to its broad market reach. Investors should note the ongoing litigation, including product liability and antitrust cases, though the company believes it has strong defenses and that potential liabilities are largely covered by insurance. The report also mentions a potential impact from a new inhaled insulin form on its insulin device sales, which BD aims to mitigate through product strengths and market dynamics.

Key Highlights

1Becton Dickinson operates through three main segments: Medical, Diagnostics, and Biosciences, serving diverse healthcare and research markets globally.

2The company emphasizes innovation and product development, with significant R&D investments ($272 million in FY2005), aiming to maintain a competitive edge.

3BDX has a significant international presence, with manufacturing and sales operations across North America, Europe, Asia, and Latin America.

4The company is facing several legal proceedings, including product liability lawsuits related to latex gloves and needlestick injuries, as well as antitrust litigation. BD believes it has strong defenses and insurance coverage.

5A divestiture of the Clontech unit from the BD Biosciences segment was completed in August 2005.

6BDX is actively repurchasing its stock, with over 2.6 million shares bought back in the fiscal quarter ending September 30, 2005, under a program authorized in late 2004.

7The company notes potential competition from new inhaled insulin forms, which could affect sales of its current insulin injection devices, though it believes its products remain competitive.

BECTON DICKINSON & CO Annual Report, Year Ended Sep 30, 2005

Summary

Key Highlights

Frequently Asked Questions